Skip to main content
. Author manuscript; available in PMC: 2018 Feb 5.
Published in final edited form as: Vet Comp Oncol. 2016 Aug 9;15(4):1240–1256. doi: 10.1111/vco.12260

Figure 6.

Figure 6

Effects of brentuximab vedotin on proliferation of IL-4-exposed NI-1 and C2 cells. (A, B) NI-1 and C2 cells were pre-incubated with 200 ng mL−1 recombinant canine IL-4 (A), recombinant human IL-4 (B) or control medium at 37 °C for 48 h. Then, cells were treated with various concentrations of brentuximab vedotin (plus 200 ng mL−1 IL-4) for 96 h. Thereafter, 3H-thymidine uptake was measured. Results are expressed as percent of control (co) and represent the mean ± SD of three independent experiments. Asterisk (*): P <0.05.